Longeveron (LGVN) Financials

Longeveron (NASDAQ: LGVN) continues to operate like a development-stage biotech: modest revenue, heavy operating losses, and a business model that still depends on external financing to fund research and operations. The good news is that the company ended Q1 2026 with a much stronger cash position after a sizeable financing raise. The less encouraging news is that revenue remains small relative to spending, so losses and cash burn are still the dominant story.

Quarter-over-quarter, Q1 2026 showed improvement in a few key areas. Revenue rose to $398,000 from $365,000 in Q4 2025, and gross profit edged up to $264,000. Operating expenses also came down sharply to $5.0 million from $5.7 million in the prior quarter, helped by lower SG&A and R&D spending. Even so, LGVN still posted a net loss of $4.7 million for the quarter.

Cash flow improved dramatically on the surface because of financing activity. LGVN generated a net increase in cash and equivalents of $11.1 million in Q1 2026, driven by $13.4 million of preferred equity issuance and $1.3 million of common equity issuance. That pushed cash and equivalents to $15.8 million at quarter-end, up from $9.2 million at the end of Q3 2025 and $10.3 million at the end of Q2 2025.

However, operating cash burn remains significant. The company used $4.37 million in operating cash during Q1 2026, only slightly better than the $5.30 million burned in Q4 2025 and still consistent with a company that is not yet self-funding. For retail investors, that means the balance sheet is being supported by dilutive capital raises rather than positive cash generation.

• Cash balance improved materially to $15.8 million in Q1 2026 from $9.2 million in Q3 2025, giving the company more near-term flexibility.
• Operating expenses declined to $5.0 million from $5.7 million in Q4 2025, suggesting some cost control.
• Net loss narrowed to $4.7 million from $5.4 million in Q4 2025.
• Revenue ticked higher to $398,000 from $365,000 sequentially.
• Gross profit improved slightly to $264,000, indicating the company is still producing positive gross margins on its revenue base.
• Financing activity boosted liquidity, but it was the main reason cash increased, not operating performance.
• Balance sheet equity increased to $16.0 million from $9.97 million in Q3 2025, largely reflecting new capital raises.
• Operating cash burn remains high at $4.37 million for the quarter.
• Losses still far exceed revenue, with quarterly revenue under $0.4 million versus millions in operating expenses.
• Share issuance remains a dependency, which can dilute existing shareholders over time.

Looking at the longer trend, LGVN’s quarterly revenue has been volatile but generally low, ranging from roughly $137,000 to $773,000 across the periods provided, while operating expenses have stayed in the multi-million-dollar range. That gap has produced recurring quarterly losses for years. The company’s net income has remained negative every quarter in the dataset, and earnings per share have been deeply negative as well.

The balance sheet has also changed meaningfully over the last year. Total assets were $21.2 million in Q1 2026, up from $15.6 million in Q3 2025, while total liabilities were $5.2 million versus $5.6 million in Q3 2025. That leaves LGVN with positive common equity of $16.0 million. Still, the improvement appears driven more by financing and equity issuance than by internal profitability.

Bottom line: Longeveron has bought itself more runway with a strong Q1 2026 financing round, and it did make some progress on expenses. But investors should recognize that this is still a cash-consuming biotech with limited revenue and ongoing dilution risk. The key question going forward is whether the company can convert its clinical and business progress into a meaningful, repeatable revenue stream before it has to return to the market for more capital.